Clinical Trial Detail

NCT ID NCT02929576
Title Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR)
Recruitment Withdrawn
Gender both
Phase Phase III
Variant Requirements No
Sponsors Medivation, Inc.
Indications

triple-receptor negative breast cancer

Therapies

Paclitaxel

Enzalutamide + Paclitaxel

Enzalutamide

Age Groups: adult senior

No variant requirements are available.